P/B
—
MannKind
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of inhaled therapeutic products for patients with diseases such as diabetes and pulmonary arterial hypertension. Its approved product, Afrezza (insulin human) Inhalation Powder, is an ultra-rapid-acting inhaled insulin used to improve glycemic control in adults with diabetes. The product consists of a dry powder formulation of human insulin delivered from a small portable inhaler.
$1B
Market Cap • 10/23/2026
1991
(35 years)
Founded
2004
(22 years ago)
IPO
NASDAQ
Listing Exchange
United States
Country
Valuation
P/S
2,6
P/EBITDA
32,9
P/OCF
—
P/FCF
—
P/E
—
BVPS
—
EPS
—
Market Cap
Market Cap
1B
EV
1,2B
EV/Revenue
3,2
EV/EBITDA
39,9
EV/EBIT
135,3
Payout
Dividend Per Share
0
Dividend Yield
0%
Buyback Yield
-0,3%
Total Yield
-0,3%
Payout
0%
Retained Earnings
-3,2B
Profitability
Gross Margin
75,4%
EBITDA Margin
7,9%
EBIT Margin
2,3%
Net Margin
—
D&A/EBITDA
0%
R&D/Revenue
19,5%
Capex/Revenue
2,6%
Capex/D&A
45,9%
Capex/OCF
-125,2%
SBC/OCF
—
% PPE
11,6%
% Goodwill
9,2%
ROE
71,4%
ROIC
2,5%
Growth
CAGR Revenue 5Y
39,5%
CAGR Net Income 5Y
-12,7%
CAGR EPS 5Y
-18%
CAGR OCF 5Y
-30%
Leverage
N.D./EBITDA
7
Debt/Equity
0%
Current Ratio
1,7
Quick Ratio
1,1
Interest Coverage
19%
Premium
- Unrestricted access
- Unlimited data history
- Analysis videos
- Quarterly highlights
- Customizable financials table
- Ranking
- Discussions
...and much more!